84-1468-63　［取扱停止］PIP5K1A, NT (Phosphatidylinositol-4-phosphate 5-kinase Type-1 alpha, PtdIns(4)P-5-Kinase alpha, PIP5KI-alpha, Phosphatidylinositol-4-phosphate 5-kinase Type I alpha, 68kD Type I Phosphatidylinositol-4-phosphate 5-kinase alpha, PIP5KIalpha) (AP) 200ul　P4071-76A-AP

特徴

• Overexpression of phosphatidylinositol phosphate 5-kinase alpha (PIP5KIalpha), which synthesizes PIP2, suppresses apoptosis, whereas a kinase-deficient mutant does not.
• Protection by the wild-type PIP5KIalpha isaccompanied by decreases in the generation of activated caspases and of caspase 3-cleaved PARP.
• Protection is not mediated through PIP3 or Akt activation.
• An anti-apoptotic role for PIP(2) is substantiated by the finding that PIP5KIalpha is cleaved by caspase 3 during apoptosis, and cleavage inactivates PIP5KIalpha in vitro.
• Mutation of the P(4) position (D279A) of the PIP5KIalpha caspase 3 cleavage consensus prevents cleavage in vitro, and during apoptosis in vivo.
• Significantly, the caspase 3-resistant PIP5KIalpha mutant is more effective in suppressing apoptosis than the wild-type kinase.
• PIP2 is a direct regulator of apical and effector caspases in the death receptor and mitochondrial pathways, and PIP5KIalpha inactivation contributes to the progression of apoptosis.
• Applications:Suitable for use in ELISA and Western Blot.
• Other applications not tested.
• Recommended Dilution:ELISA: 1:1,000 Western Blot: 1:100-1:500Optimal dilutions to be determined by the researcher.
• Storage and Stability:Store product at 4°C.
• DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid.
• Dilute required amount only prior to immediate use.
• Further dilutions can be made in assay buffer.
• For maximum recovery of product, centrifuge the original vial prior to removing the cap.
• Note: Applications are based on unconjugated antibody.